Ona Therapeutics

Oncology

In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.

News

Longevity biotech NewLimit's $435m Series C heads this week's round-up of biotech venture capital financings.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.